Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kerri Langer

Psychiatry Aurora, CO Medical Doctor

NPI 1184943920 CMS profile 425652

13001 E 17Th Pl, University Of Colorado Denver School Of Medicine Gme, Aurora, CO 80045

Open in the dashboard

General payments

$4,448

239 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kerri Langer of Aurora, CO is reported in the CMS Open Payments database as having received $4,448 across 239 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $881 49
2024 General $636 26
2023 General $809 41
2022 General $428 24
2021 General $218 13
2020 General $274 15
2019 General $1,202 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kerri Langer
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Kerri Langer were reported at $881. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Kerri Langer Psychiatry median Middle half National median
2019 $1,202 $184 $59–$605 $163
2020 $274 $119 $36–$372 $114
2021 $218 $143 $43–$576 $132
2022 $428 $153 $50–$590 $149
2023 $809 $170 $56–$651 $160
2024 $636 $179 $57–$673 $164
2025 $881 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $726 50 payments
  2. Neurocrine Biosciences, Inc. $499 20 payments
  3. Lundbeck LLC $472 24 payments
  4. Otsuka America Pharmaceutical, Inc. $391 20 payments
  5. Teva Pharmaceuticals USA, Inc. $332 16 payments
  6. Alkermes, Inc. $307 13 payments
  7. Allergan Inc. $296 22 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $262 11 payments
  9. ITI, Inc. $239 11 payments
  10. Sunovion Pharmaceuticals Inc. $202 15 payments
  11. Other $720 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,376 238 payments
  2. Education $71 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $513 40 payments
  2. VRAYLAR Neuroscience $498 30 payments
  3. INGREZZA $406 15 payments
  4. LYBALVI $307 13 payments
  5. ARISTADA Cns $288 12 payments
  6. ARISTADA Cns $288 12 payments
  7. REXULTI Psychiatry $275 14 payments
  8. BRINTELLIX $240 12 payments
  9. REXULTI Psychiatry $233 12 payments
  10. TRINTELLIX $207 9 payments
  11. Other $2,509 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

44

Median for Psychiatry & Neurology: 100

Drug cost

$963

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clonazepam Generic 33 $509
Lamotrigine Generic 11 $454

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ARISTADA
  • Alkermes, Inc. $79
$79 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $68
$68 — —
VRAYLAR
  • AbbVie, Inc. $68
$68 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $64
$64 — —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record